{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:09:36Z","timestamp":1787724576420,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874132"],"award-info":[{"award-number":["81874132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672687"],"award-info":[{"award-number":["81672687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hainan Province","doi-asserted-by":"publisher","award":["2019JJ40486"],"award-info":[{"award-number":["2019JJ40486"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["KQTD20170810160226082"],"award-info":[{"award-number":["KQTD20170810160226082"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>EphA2 is an important oncogenic protein and emerging drug target, but the oncogenic role and mechanism of ligand-independent phosphorylation of EphA2 at tyrosine 772 (pY772-EphA2) is unclear. In this study, we established nasopharyngeal carcinoma (NPC) cell lines with stable expression of exogenous EphA2 and EphA2-Y772A (phosphorylation inactivation) using endogenous EphA2-knockdown cells, and observed that pY772A EphA2 was responsible for EphA2-promoting NPC cell proliferation and anchorage-independent and in vivo growth in mice. Mechanistically, EphA2-Y772A mediated EphA2-activating Shp2\/Erk-1\/2 signaling pathway in the NPC cells, and Gab1 (Grb2-associated binder 1) and Grb2 (growth factor receptor-bound protein 2) were involved in pY772-EphA2 activating this signaling pathway. Our results further showed that Shp2\/Erk-1\/2 signaling mediated pY772-EphA2-promoting NPC cell proliferation and anchorage-independent growth. Moreover, we observed that EphA2 tyrosine kinase inhibitor ALW-II-41-27 inhibited pY772-EphA2 and EphA2-Y772A decreased the inhibitory effect of ALW-II-41-27 on NPC cell proliferation. Collectively, our results demonstrate that pY772-EphA2 is responsible for EphA2-dependent NPC cell growth in vitro and in vivo by activating Shp2\/Erk-1\/2 signaling pathway, and is a pharmacologic target of ALW-II-41-27, suggesting that pY772-EphA2 can serve as a therapeutic target in NPC and perhaps in other cancers.<\/jats:p>","DOI":"10.1038\/s41419-020-02831-0","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:10:04Z","timestamp":1598487004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Y772 phosphorylation of EphA2 is responsible for EphA2-dependent NPC nasopharyngeal carcinoma growth by Shp2\/Erk-1\/2 signaling pathway"],"prefix":"10.1038","volume":"11","author":[{"given":"Yi-Ping","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Ya","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Hui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Yun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"2831_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1535-6108(04)00119-9","volume":"5","author":"KW Lo","year":"2004","unstructured":"Lo, K. W., To, K. F. & Huang, D. P. Focus on nasopharyngeal carcinoma. Cancer Cell 5, 423\u2013428 (2004).","journal-title":"Cancer Cell"},{"issue":"Suppl 3","key":"2831_CR2","doi-asserted-by":"publisher","first-page":"S302","DOI":"10.1016\/S0959-8049(11)70179-4","volume":"47","author":"AT Chan","year":"2011","unstructured":"Chan, A. T. Current treatment of nasopharyngeal carcinoma. Eur. J. Cancer 47(Suppl 3), S302\u2013S303 (2011).","journal-title":"Eur. J. Cancer"},{"key":"2831_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","volume":"10","author":"EB Pasquale","year":"2010","unstructured":"Pasquale, E. B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10, 165\u2013180 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"2831_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","volume":"16","author":"H Miao","year":"2009","unstructured":"Miao, H. et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9\u201320 (2009).","journal-title":"Cancer Cell"},{"key":"2831_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcdb.2011.10.013","volume":"23","author":"H Miao","year":"2012","unstructured":"Miao, H. & Wang, B. EphA receptor signaling-complexity and emerging themes. Semin Cell Dev. Biol. 23, 16\u201325 (2012).","journal-title":"Semin Cell Dev. Biol."},{"key":"2831_CR6","doi-asserted-by":"publisher","first-page":"ra15","DOI":"10.1126\/scisignal.aac5820","volume":"9","author":"M Locard-Paulet","year":"2016","unstructured":"Locard-Paulet, M. et al. Phosphoproteomic analysis of interacting tumor and endothelial cells identifies regulatory mechanisms of transendothelial migration. Sci. Signal. 9, ra15 (2016).","journal-title":"Sci. Signal."},{"key":"2831_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/35000008","volume":"2","author":"H Miao","year":"2000","unstructured":"Miao, H., Burnett, E., Kinch, M., Simon, E. & Wang, B. Activation of EphA2 kinase suppresses integrin function and causes focal- adhesion-kinase dephosphorylation. Nat. Cell Biol. 2, 62\u201369 (2000).","journal-title":"Nat. Cell Biol."},{"key":"2831_CR8","first-page":"1922","volume":"9","author":"DR Singh","year":"2017","unstructured":"Singh, D. R., Pasquale, E. B. & Hristova, K. A. Small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim. Biophys. Acta 9, 1922\u20131928 (2017).","journal-title":"Biochim. Biophys. Acta"},{"key":"2831_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1248\/bpb.b17-00446","volume":"10","author":"Y Zhou","year":"2017","unstructured":"Zhou, Y. & Sakurai, H. Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression. Biol. Pharm. Bull. 10, 1616\u20131624 (2017).","journal-title":"Biol. Pharm. Bull."},{"key":"2831_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ccr.2012.11.005","volume":"22","author":"E Binda","year":"2012","unstructured":"Binda, E. et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22, 765\u2013780 (2012).","journal-title":"Cancer Cell"},{"key":"2831_CR11","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1158\/0008-5472.CAN-13-2136","volume":"74","author":"W Song","year":"2014","unstructured":"Song, W., Ma, Y., Wang, J., Brantley-Sieders, D. & Chen, J. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res. 74, 2444\u20132454 (2014).","journal-title":"Cancer Res."},{"key":"2831_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.fob.2013.01.002","volume":"3","author":"H Kawai","year":"2013","unstructured":"Kawai, H. et al. Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2. FEBS Open Bio 3, 78\u201382 (2013).","journal-title":"FEBS Open Bio"},{"key":"2831_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-14-0293","volume":"5","author":"KH Paraiso","year":"2015","unstructured":"Paraiso, K. H. et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 5, 264\u2013273 (2015).","journal-title":"Cancer Discov."},{"key":"2831_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/onc.2013.590","volume":"34","author":"H Miao","year":"2015","unstructured":"Miao, H. et al. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene 34, 558\u2013567 (2015).","journal-title":"Oncogene"},{"key":"2831_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8679","volume":"6","author":"Y Zhou","year":"2015","unstructured":"Zhou, Y. et al. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. Nat. Commun. 6, 7679 (2015).","journal-title":"Nat. Commun."},{"key":"2831_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/febs.12000","volume":"280","author":"WJ Hendriks","year":"2013","unstructured":"Hendriks, W. J. et al. Protein tyrosine phosphatases in health and disease. FEBS J. 280, 708\u2013730 (2013).","journal-title":"FEBS J."},{"key":"2831_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","volume":"27","author":"G Chan","year":"2008","unstructured":"Chan, G., Kalaitzidis, D. & Neel, B. G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27, 179\u2013192 (2008).","journal-title":"Cancer Metastasis Rev."},{"key":"2831_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","volume":"106","author":"KS Grossmann","year":"2010","unstructured":"Grossmann, K. S., Rosario, M., Birchmeier, C. & Birchmeier, W. The tyrosine phosphatase Shp2 in development and cancer. Adv. Cancer Res. 106, 53\u201389 (2010).","journal-title":"Adv. Cancer Res."},{"key":"2831_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1158\/1541-7786.MCR-18-0777","volume":"17","author":"KS Hill","year":"2019","unstructured":"Hill, K. S. et al. PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas. Mol. Cancer Res. 17, 583\u2013593 (2019).","journal-title":"Mol. Cancer Res."},{"key":"2831_CR20","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1172\/JCI130520","volume":"129","author":"R Pandey","year":"2019","unstructured":"Pandey, R. et al. SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations. J. Clin. Invest. 129, 5468\u20135473 (2019).","journal-title":"J. Clin. Invest."},{"key":"2831_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","volume":"24","author":"S Mainardi","year":"2018","unstructured":"Mainardi, S. et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat. Med. 24, 961\u2013967 (2018).","journal-title":"Nat. Med."},{"key":"2831_CR22","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1038\/s41388-018-0574-8","volume":"38","author":"H Zhao","year":"2019","unstructured":"Zhao, H. et al. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene 38, 2275\u20132290 (2019).","journal-title":"Oncogene"},{"key":"2831_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc1837","volume":"6","author":"A Ostman","year":"2006","unstructured":"Ostman, A., Hellberg, C. & Bo\u00a8hmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6, 307\u2013320 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"2831_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.cr.7290055","volume":"10","author":"CK Qu","year":"2000","unstructured":"Qu, C. K. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res. 10, 279\u2013288 (2000).","journal-title":"Cell Res."},{"key":"2831_CR25","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1128\/MCB.20.5.1526-1536.2000","volume":"20","author":"ZQ Shi","year":"2000","unstructured":"Shi, Z. Q., Yu, D. H., Park, M., Marshall, M. & Feng, G. S. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol. Cell Biol. 20, 1526\u20131536 (2000).","journal-title":"Mol. Cell Biol."},{"key":"2831_CR26","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1128\/MCB.16.3.1189","volume":"16","author":"AM Bennett","year":"1996","unstructured":"Bennett, A. M., Hausdorff, S. F., O\u2019Reilly, A. M., Freeman, R. M. & Neel, B. G. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol. Cell Biol. 16, 1189\u20131202 (1996).","journal-title":"Mol. Cell Biol."},{"key":"2831_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1172\/JCI33154","volume":"118","author":"DM Brantley-Sieders","year":"2008","unstructured":"Brantley-Sieders, D. M. et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 118, 64\u201378 (2008).","journal-title":"J. Clin. Invest."},{"key":"2831_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1568009053765780","volume":"5","author":"RC Ireton","year":"2005","unstructured":"Ireton, R. C. & Chen, J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr. Cancer Drug Targets 5, 149\u2013157 (2005).","journal-title":"Curr. Cancer Drug Targets"},{"key":"2831_CR29","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1038\/onc.2012.571","volume":"32","author":"K Miura","year":"2013","unstructured":"Miura, K. et al. Involvement of EphA2- mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene 32, 5292\u20135301 (2013).","journal-title":"Oncogene"},{"key":"2831_CR30","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1016\/j.bmcl.2009.05.029","volume":"19","author":"Y Choi","year":"2009","unstructured":"Choi, Y. et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 19, 4467\u20134470 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2831_CR31","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1172\/JCI72522","volume":"5","author":"KR Amato","year":"2014","unstructured":"Amato, K. R. et al. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J. Clin. Invest. 5, 2037\u20132049 (2014).","journal-title":"J. Clin. Invest."},{"key":"2831_CR32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/0008-5472.CAN-15-0717","volume":"76","author":"KR Amato","year":"2016","unstructured":"Amato, K. R. et al. EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer. Cancer Res. 76, 305\u2013318 (2016).","journal-title":"Cancer Res."},{"key":"2831_CR33","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.bbrc.2019.09.076","volume":"519","author":"H Ishigaki","year":"2019","unstructured":"Ishigaki, H. et al. EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest. Biochem. Biophys. Res. Commun. 519, 846\u2013853 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2831_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2159-8290.CD-14-0295","volume":"5","author":"B Miao","year":"2015","unstructured":"Miao, B. et al. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 5, 274\u2013287 (2015).","journal-title":"Cancer Discov."},{"key":"2831_CR35","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1038\/onc.2017.170","volume":"36","author":"W Song","year":"2017","unstructured":"Song, W. et al. Targeting EphA2 impairs cell cycle progression and growth of basal-like\/triple-negative breast cancers. Oncogene 36, 5620\u20135630 (2017).","journal-title":"Oncogene"},{"key":"2831_CR36","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/ijc.31979","volume":"144","author":"Y Sheng","year":"2019","unstructured":"Sheng, Y. et al. Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma. Int J. Cancer 144, 2440\u20132452 (2019).","journal-title":"Int J. Cancer"},{"key":"2831_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2018.12.011","volume":"444","author":"JY Li","year":"2019","unstructured":"Li, J. Y. et al. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties. Cancer Lett. 444, 162\u2013174 (2019).","journal-title":"Cancer Lett."},{"key":"2831_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","volume":"20","author":"M Dance","year":"2008","unstructured":"Dance, M., Montagner, A., Salles, J. P., Yart, A. & Raynal, P. The molecular functions of Shp2 in the Ras\/mitogen-activated protein kinase (ERK1\/2) pathway. Cell Signal. 20, 453\u2013459 (2008).","journal-title":"Cell Signal."},{"key":"2831_CR39","doi-asserted-by":"publisher","first-page":"41677","DOI":"10.1074\/jbc.M306461200","volume":"278","author":"T Araki","year":"2003","unstructured":"Araki, T., Nawa, H. & Neel, B. G. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J. Biol. Chem. 278, 41677\u201341684 (2003).","journal-title":"J. Biol. Chem."},{"key":"2831_CR40","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1541-7786.MCR-08-0244","volume":"6","author":"J Wykosky","year":"2008","unstructured":"Wykosky, J. & Debinski, W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 6, 1795\u20131806 (2008).","journal-title":"Mol. Cancer Res."},{"key":"2831_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1517\/14728222.2011.538682","volume":"15","author":"M Tandon","year":"2011","unstructured":"Tandon, M., Vemula, S. V. & Mittal, S. K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin. Ther. Targets 15, 31\u201351 (2011).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2831_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jprot.2015.03.038","volume":"123","author":"E Scifo","year":"2015","unstructured":"Scifo, E. et al. Proteomic analysis of the palmitoyl protein thioesterase 1 interactome in SH-SY5Y human neuroblastoma cells. J. Proteomics 123, 42\u201353 (2015).","journal-title":"J. Proteomics"},{"key":"2831_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1113-9","volume":"9","author":"T Xiao","year":"2018","unstructured":"Xiao, T. et al. RACK1 promotes tumorigenicity of colon cancer by inducing cell autophagy. Cell Death Dis. 9, 1148 (2018).","journal-title":"Cell Death Dis."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02831-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T10:20:43Z","timestamp":1670235643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02831-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["2831"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-02831-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"19 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"709"}}